Methylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response

Abstract Glucocorticoids (GCs) are the main treatment of relapse in multiple sclerosis (MS). Decreased sensitivity to GCs in MS patients has been associated with lack of the suppressive effect of GCs on inflammatory molecules as well as increased resistance to apoptosis. We investigated GC-sensitivi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maria Eleftheria Evangelopoulos, Narjes Nasiri-Ansari, Eva Kassi, Anna Papadopoulou, Dimitrios Stergios Evangelopoulos, Paraskevi Moutsatsou
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4ad45d265c1143cd81200f2f89572d4a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4ad45d265c1143cd81200f2f89572d4a
record_format	dspace
spelling	oai:doaj.org-article:4ad45d265c1143cd81200f2f89572d4a2021-12-02T18:51:36ZMethylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response10.1038/s41598-021-98868-y2045-2322https://doaj.org/article/4ad45d265c1143cd81200f2f89572d4a2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-98868-yhttps://doaj.org/toc/2045-2322Abstract Glucocorticoids (GCs) are the main treatment of relapse in multiple sclerosis (MS). Decreased sensitivity to GCs in MS patients has been associated with lack of the suppressive effect of GCs on inflammatory molecules as well as increased resistance to apoptosis. We investigated GC-sensitivity by measuring the effect of intravenous methylprednisolone (IVMP) treatment on transactivation of anti-inflammatory and apoptotic genes (GILZ, MCL-1 and NOXA respectively), in accordance to clinical outcome. Thirty nine MS patients were studied: 15 with clinically isolated syndrome (CIS), 12 with relapsing remitting (RRMS) and 12 with secondary progressive (SPMS) under relapse. Patients underwent treatment with IVMP for 5 days. Blood was drawn before IVMP treatment on day 1 and 1 h after IVMP treatment on days 1 and 5. GIlZ, MCL-1 and NOXA were determined by qPCR. The Expanded Disability Status was evaluated and patients were divided according to their clinical response to IVMP. GILZ and MCL-1 gene expression were significantly higher following first IVMP treatment in responders, compared to non-responders. Furthermore, serum basal cortisol and 1,25-OH Vitamin D levels were significantly higher in clinical-responders as compared to non-clinical responders. Our findings suggest that the differential GILZ and MCL-1 gene expression between clinical-responders and non-clinical responders may implicate the importance of GILZ and MCL-1 as possible markers for predicting glucocorticoid sensitivity and response to GC-therapy in MS patients following first IVMP injection.Maria Eleftheria EvangelopoulosNarjes Nasiri-AnsariEva KassiAnna PapadopoulouDimitrios Stergios EvangelopoulosParaskevi MoutsatsouNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Maria Eleftheria Evangelopoulos Narjes Nasiri-Ansari Eva Kassi Anna Papadopoulou Dimitrios Stergios Evangelopoulos Paraskevi Moutsatsou Methylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response
description	Abstract Glucocorticoids (GCs) are the main treatment of relapse in multiple sclerosis (MS). Decreased sensitivity to GCs in MS patients has been associated with lack of the suppressive effect of GCs on inflammatory molecules as well as increased resistance to apoptosis. We investigated GC-sensitivity by measuring the effect of intravenous methylprednisolone (IVMP) treatment on transactivation of anti-inflammatory and apoptotic genes (GILZ, MCL-1 and NOXA respectively), in accordance to clinical outcome. Thirty nine MS patients were studied: 15 with clinically isolated syndrome (CIS), 12 with relapsing remitting (RRMS) and 12 with secondary progressive (SPMS) under relapse. Patients underwent treatment with IVMP for 5 days. Blood was drawn before IVMP treatment on day 1 and 1 h after IVMP treatment on days 1 and 5. GIlZ, MCL-1 and NOXA were determined by qPCR. The Expanded Disability Status was evaluated and patients were divided according to their clinical response to IVMP. GILZ and MCL-1 gene expression were significantly higher following first IVMP treatment in responders, compared to non-responders. Furthermore, serum basal cortisol and 1,25-OH Vitamin D levels were significantly higher in clinical-responders as compared to non-clinical responders. Our findings suggest that the differential GILZ and MCL-1 gene expression between clinical-responders and non-clinical responders may implicate the importance of GILZ and MCL-1 as possible markers for predicting glucocorticoid sensitivity and response to GC-therapy in MS patients following first IVMP injection.
format	article
author	Maria Eleftheria Evangelopoulos Narjes Nasiri-Ansari Eva Kassi Anna Papadopoulou Dimitrios Stergios Evangelopoulos Paraskevi Moutsatsou
author_facet	Maria Eleftheria Evangelopoulos Narjes Nasiri-Ansari Eva Kassi Anna Papadopoulou Dimitrios Stergios Evangelopoulos Paraskevi Moutsatsou
author_sort	Maria Eleftheria Evangelopoulos
title	Methylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response
title_short	Methylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response
title_full	Methylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response
title_fullStr	Methylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response
title_full_unstemmed	Methylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response
title_sort	methylprednisolone stimulated gene expression (gilz, mcl-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/4ad45d265c1143cd81200f2f89572d4a
work_keys_str_mv	AT mariaeleftheriaevangelopoulos methylprednisolonestimulatedgeneexpressiongilzmcl1andbasalcortisollevelsinmultiplesclerosispatientsinrelapseareassociatedwithclinicalresponse AT narjesnasiriansari methylprednisolonestimulatedgeneexpressiongilzmcl1andbasalcortisollevelsinmultiplesclerosispatientsinrelapseareassociatedwithclinicalresponse AT evakassi methylprednisolonestimulatedgeneexpressiongilzmcl1andbasalcortisollevelsinmultiplesclerosispatientsinrelapseareassociatedwithclinicalresponse AT annapapadopoulou methylprednisolonestimulatedgeneexpressiongilzmcl1andbasalcortisollevelsinmultiplesclerosispatientsinrelapseareassociatedwithclinicalresponse AT dimitriosstergiosevangelopoulos methylprednisolonestimulatedgeneexpressiongilzmcl1andbasalcortisollevelsinmultiplesclerosispatientsinrelapseareassociatedwithclinicalresponse AT paraskevimoutsatsou methylprednisolonestimulatedgeneexpressiongilzmcl1andbasalcortisollevelsinmultiplesclerosispatientsinrelapseareassociatedwithclinicalresponse
_version_	1718377383610810368

Methylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response

Ejemplares similares